Psilocybin neurogenesis may offer a biological clue to how psychedelic treatments produce effects that continue after the drug has left the body. A new preclinical study reports that psilocybin increased markers of new neuron development while improving depression-like and anxiety-like behaviors in chronically stressed rats.
The findings connect behavioral recovery with changes in the hippocampus, brain-derived neurotrophic factor, and the hormonal system that regulates stress. Although animal results cannot establish the same effects in people, the study provides a detailed model for investigating how psilocybin might repair stress-related disruptions across several biological systems.
Why Current Depression Treatments Leave Important Questions
Conventional antidepressants can be effective, but their benefits may take weeks to emerge, and some patients do not respond adequately. Researchers are therefore investigating faster-acting approaches, including psilocybin administered within structured clinical protocols.
Clinical trials have shown that psilocybin therapy can reduce depressive symptoms in some patients. Yet the mechanisms supporting those changes remain unsettled. One possibility is that psilocybin temporarily increases the brain’s capacity to adapt, allowing damaged or weakened neural systems to reorganize.
Testing Psilocybin After Chronic Stress
Researchers used adult male rats exposed to chronic unpredictable mild stress, a laboratory model designed to produce behavioral and biological changes associated with prolonged stress. One measurable consequence is anhedonia, represented in this model by reduced preference for a sweet solution.
The animals received two subcutaneous doses of psilocybin at 0.6 milligrams per kilogram, separated by seven days. Investigators then assessed reward-seeking behavior, anxiety-like responses, coping behavior, hippocampal cell development, BDNF expression, and hypothalamic-pituitary-adrenal axis activity.
This design matters because it examined several levels of response simultaneously. Rather than relying on a single behavioral test, the researchers compared observable behavior with cellular growth markers and stress-hormone regulation.
Psilocybin Neurogenesis Appeared Alongside Behavioral Recovery
Chronic stress reduced sucrose preference in the rats, consistent with an anhedonia-like state. Psilocybin reversed this reduction after both doses. Treated animals also demonstrated antidepressant-like effects in the forced swim test and anxiety-reducing effects across the light-dark box, elevated plus maze, and open-field tests.
Within the hippocampus, psilocybin increased cells positive for BrdU, DCX, and Ki-67. These markers capture related but distinct stages of cell proliferation, immature neuron development, and cell survival. Their combined increase supports the interpretation that psilocybin stimulated hippocampal neurogenesis in the stressed animals.
The treatment also increased BDNF levels in the hippocampus and frontal cortex. BDNF is a protein involved in neuronal survival, synaptic adaptation, and the formation of new connections.
A Link Between Plasticity And Stress Regulation
The hippocampus helps regulate memory, emotion, and the body’s response to stress. Prolonged stress can suppress hippocampal neurogenesis, reduce plasticity-related proteins, and overactivate the hypothalamic-pituitary-adrenal axis. This can sustain elevated corticosterone levels and further weaken neural resilience.
Psilocybin appeared to act across this interconnected system. Increased BDNF may have supported cellular growth and adaptation, while normalization of corticosterone suggested improved regulation of the stress response. The behavioral improvements therefore occurred alongside measurable neuroplastic and neuroendocrine changes.
Previous research in mice found that a single psilocybin dose rapidly increased dendritic spine formation in the frontal cortex, with some structural changes persisting for at least one month. The new rat study extends that framework by connecting psilocybin with markers of new neuron development under chronic stress conditions.
What The Findings Mean For Psychedelic Research
The study does not demonstrate that psilocybin creates new neurons in human patients or that neurogenesis alone explains its therapeutic effects. The experiment involved male rats, behavioral proxies, and a dosing model that differs from supervised human treatment.
Its value lies in showing that behavioral recovery, neural plasticity, and stress-hormone regulation may move together. Future studies can test whether these changes are necessary for improvement, how long they persist, and whether comparable biological signals appear in people receiving psilocybin-assisted therapy.
For the field, the findings sharpen an important hypothesis: psilocybin may do more than temporarily alter perception. Under controlled conditions, it may open a period in which stress-affected brain systems become more capable of biological and behavioral change.
Citations
Bysiek A, et al. “Psilocybin Restores Behavioral and Neuroplastic Deficits Induced by Chronic Stress in Rats.” Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026. PubMed
Shao LX, et al. “Psilocybin Induces Rapid and Persistent Growth of Dendritic Spines in Frontal Cortex In Vivo.” Neuron, 2021. PubMed
Explore more at https://www.interventionalpsychiatry.org/
